Document Detail

Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors.
MedLine Citation:
PMID:  8513428     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To focus on the cardioprotective role of angiotensin-converting enzyme (ACE) inhibitors in ischemic heart disease and to highlight some of the, as yet, unanswered questions about the relative merits of ACE inhibitors as cardioprotective drugs. DATA SOURCE: This review incorporates the data on this subject published in the available English literature up to June 1990. DATA SELECTION: The source material was analyzed and computed chronologically into two groups: experimental studies and clinical trials. DATA EXTRACTION: ACE inhibitors have gained access to the free world market for a variety of reasons. Their superiority in the management of hypertension and congestive heart failure is being recognized. Furthermore, recent experimental and limited clinical trials strongly indicate a role for ACE inhibitors in limiting myocardial ischemia-reperfusion-induced injury. Although the sulphydryl group (SH)-containing ACE inhibitor captopril has been extensively used for most studies, the cardioprotective role of non-SH-containing ACE inhibitors, particularly ramipril and enalapril, recently has been identified. ACE inhibitors reportedly limit infarct size, prevent ventricular remodelling and, more importantly, stabilize the electrical activity of the reperfused heart and prevent the occurrence of reperfusion arrhythmias. Preliminary clinical trials indicate an antianginal role for ACE inhibitors. ACE inhibition has also been reported to improve left ventricular performance in patients with long standing infarcts and ischemic failure. Although pharmacological effects of ACE inhibitors are well known, the mechanism of cardioprotection at the molecular and cellular levels is elusive. The role of ACE inhibitors in myocardial stunning and their free radical scavenging effects are still speculative. Furthermore, the effects of ACE inhibition during global myocardial ischemia-reperfusion are virtually unknown. CONCLUSIONS: The available data strongly indicates a role for ACE inhibitors in limiting myocardial ischemia-reperfusion-induced injury. However, more controlled studies, particularly multicentre clinical trials, are indicated to establish a therapeutic rationale for ACE inhibition in the management of ischemic heart disease.
J S Juggi; E Koenig-Berard; W H Van Gilst
Related Documents :
22198008 - Allograft pathology in patients transplanted for idiopathic dilated cardiomyopathy.
22293798 - Increased serum bilirubin level is related to good collateral development in patients w...
21716108 - Increased blood troponin levels in icu patients.
21140118 - Clinics in diagnostic imaging (132). vein of galen malformation.
6608928 - Calcium channel blockers: an intraoperative and postoperative trial in women.
15337218 - Impact of physical deconditioning on ventricular tachyarrhythmias in trained athletes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  9     ISSN:  0828-282X     ISO Abbreviation:  Can J Cardiol     Publication Date:  1993 May 
Date Detail:
Created Date:  1993-07-22     Completed Date:  1993-07-22     Revised Date:  2008-04-09    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  336-52     Citation Subset:  IM    
Institute de recherches Internationales Servier, Courbevoie, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use*
Heart Failure / drug therapy
Hypertension / drug therapy
Myocardial Ischemia / drug therapy*
Myocardial Reperfusion Injury / drug therapy*
Renin-Angiotensin System / drug effects
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary artery fistula as a complication of percutaneous transluminal coronary angioplasty.
Next Document:  Maximal short-term exercise performance and ion regulation in cystic fibrosis.